The UVA scientists, led by Charles E. Chalfant, found they could predict the risk of preeclampsia by examining lipids, or fats, in women’s blood during pregnancy. The researchers say their finding opens the door for simple blood tests to screen patients.

Researchers said the approach worked regardless of whether the women were on aspirin therapy, commonly prescribed to women thought to be at risk.

The discovery by UVA researchers led by Charles E. Chalfant could lead to a simple blood test that could tell doctors whether a pregnant woman is at risk for a serious complication. (Contributed photo)

“Although alterations in some blood lipid levels have been known to occur in preeclampsia, they have not been endorsed as useful biomarkers,” said Chalfant, of the School of Medicine’s Division of Hematology and Oncology and the Department of Cell Biology. “The lipid ‘signature’ we described could significantly improve the ability to identify patients needing preventative treatment, like aspirin, or more careful monitoring for early signs of disease so that treatment could be initiated in a timely fashion.”

Preeclampsia affects up to 7% of all pregnancies. Symptoms typically appear after 20 weeks and include high blood pressure, kidney problems and abnormalities in blood clotting. The condition also is associated with dangerous complications such as liver dysfunction, seizures as well as a lifelong increased risk of heart disease for the mothers. An estimated 70,000 women around the world die from preeclampsia and its complications each year. 

Doctors commonly recommend low-dose aspirin for at-risk women, but it works for only about half of patients and needs to be started within the first 16 weeks of pregnancy. That’s well before symptoms appear, which makes it more important to identify women at risk early on, and to better understand preeclampsia in general.

Chalfant and his team wanted to find biological indicators in the blood of pregnant women that could reveal their risk of developing preeclampsia. They examined blood plasma samples collected from 57 women in their first 24 weeks of pregnancy, then looked at whether the women went on to develop preeclampsia. The researchers found significant differences in “bioactive lipids” in the blood of women who developed preeclampsia and those who did not.  

This, the researchers say, should allow doctors to judge women’s risk of developing preeclampsia by measuring lipid changes in their blood. The changes represent an important “lipid fingerprint,” the scientists say, that could be a useful tool for identifying, preventing and better treating the condition. 

“The application of our comprehensive lipid profiling method to routine obstetrical care could significantly reduce maternal and neonatal morbidity and mortality,” Chalfant said. “It represents an example of how personalized medicine could address a significant public health challenge.”

The researchers have published their findings in the Journal of Lipid Research. The multi-disciplinary team consisted of Daniel J. Stephenson, H. Patrick MacKnight, L. Alexis Hoeferlin, Sonya L. Washington, Chelsea Sawyers, Kellie J. Archer, Jerome F. Strauss III, Scott W. Walsh and Chalfant. The researchers have no financial interests in the work.

To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog.